Daewoong Pharmaceutical Launches Second Combination Drug 'Enblomet' Six Months After Diabetes New Drug 'Enblo' Release

Daewoong Pharmaceutical announced on the 8th that it has launched ‘Enblomet Sustained-release Tablets,’ a two-drug combination of Enblo (active ingredient Inavogliflozin), the first domestic SGLT-2 inhibitor class diabetes treatment, combined with metformin.

The launch of the two-drug combination ‘Enblomet’ came six months after the domestic release of Enblo Tablets, the 36th domestic new drug. Typically, the interval between the release of single-agent and combination drugs in the SGLT-2 inhibitor class is more than one year.

The price of Enblomet is 611 KRW, the same as the single-agent Enblo. It is used as a treatment for type 2 diabetes patients. It is approved as an adjunct to diet and exercise to improve glycemic control when co-administration of Inavogliflozin (0.3mg) and metformin hydrochloride (1000mg) is appropriate.

Enblomet is evaluated as a culmination of Daewoong Pharmaceutical’s research and development (R&D) capabilities. Like the single-agent Enblo Tablets, its size has been minimized to enhance patient convenience. Daewoong Pharmaceutical stated, “By applying differentiated processing techniques, patients can achieve blood sugar-lowering effects with once-daily, single-dose administration.”

Enblomet Sustained-release Tablets apply Daewoong Pharmaceutical’s innovative formulation technologies, including dual-release technology and bilayer tablet technology. The bilayer tablet technology minimizes interactions between drugs to enhance stability. The dual-release technology is a method that allows each drug to act with a time difference. Enblomet is expected to reduce gastrointestinal side effects such as nausea and diarrhea that occur when taking metformin, the first-line treatment for diabetes.

Enblomet is expected to be a meaningful treatment option in the domestic medical environment where prescriptions for combination drugs are increasing due to the continuous rise in diabetes prevalence. According to the ‘2022 Diabetes Fact Sheet’ published by the Korean Diabetes Association, combination therapy has been steadily increasing, reaching about 80% in 2019.

Chang Jae Lee, CEO of Daewoong Pharmaceutical, said, “The ability to launch a two-drug combination just six months after releasing Enblo Tablets, the first domestic SGLT-2 inhibitor new drug, is thanks to Daewoong Pharmaceutical’s R&D capabilities as a leading domestic new drug company.” He added, “We will grow it into the top new drug in the diabetes treatment class through Daewoong’s unique verified four-step strategy and differentiated sales approach, keeping pace with the continuously growing demand for combination drugs.”

This content was produced with the assistance of AI translation services.